↓ Skip to main content

RETRACTED: The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: A retrospective analysis

Overview of attention for article published in Frontiers in oncology, February 2023
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (79th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

blogs
1 blog
twitter
2 X users

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
7 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
RETRACTED: The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: A retrospective analysis
Published in
Frontiers in oncology, February 2023
DOI 10.3389/fonc.2023.1095362
Pubmed ID
Authors

Fangcheng Shen, Jing Li, Feng Liu, Ni Sun, XiangNan Qiu, Wei Ding, XiangDong Sun

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 7 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 7 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 2 29%
Professor 1 14%
Student > Bachelor 1 14%
Unknown 3 43%
Readers by discipline Count As %
Unspecified 2 29%
Social Sciences 1 14%
Medicine and Dentistry 1 14%
Unknown 3 43%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 January 2024.
All research outputs
#4,790,422
of 26,365,186 outputs
Outputs from Frontiers in oncology
#1,626
of 23,043 outputs
Outputs of similar age
#90,609
of 435,498 outputs
Outputs of similar age from Frontiers in oncology
#53
of 1,501 outputs
Altmetric has tracked 26,365,186 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 23,043 research outputs from this source. They receive a mean Attention Score of 3.2. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 435,498 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 1,501 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.